Splitomicin

Research use only, not for human use.

Splitomicin (IC50 of 60 μM), a specific inhibitor of NAD(+)-dependent histone deacetylase Sir2p, displays a high activity in a cell-based assay.

Splitomicin is a cell-permeable lactone derived from naphthol and known to be a potent selective inhibitor of Sir2 (silent information regulator 2) and HDAC. Splitomicin inhibits the NAD+-dependent deacetylase activity of Sir2 in vitro. It increases the levels of cyclic AMP by inhibiting the activity of cyclic AMP phosphodiesterase, interferes with mobilization of intracellular Ca+2 and ATP release.

Cell Proliferation Assay Cell Line:Human breast cancer MCF-7 and lung cancer H1299 cells Concentration:10, 33, 100, and 333 μM Incubation Time:24 hours Result:Inhibited colony formation in a dose-dependent manner.

Animal Model:C57BL/6 mice aged 12-14 weeks weighing on average 27 g Dosage:80 mg/kg Administration:Intraperitoneal injection every 24 h for 5 days Result:Increased TF activity in mouse carotid artery as compared with the controls.

Splitomicin

PI3K/Akt/mTOR signaling

PI3K

SIRT2p

Cardiovascular Disease

——

5690-03-9

198.22

C13H10O2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (504.49 mM)

O=C1CCc2c3ccccc3ccc2O1

1H-benzo[f]chromen-3(2H)-one

(-20℃)

With Ice Pack

≥ 2 years